AARD — Aardvark Therapeutics Share News
0.000.00%
Last trade - 00:00Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark
Aardvark slumps after FDA puts clinical hold on rare disease drug
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM
FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome
Brief: Aardvark Therapeutics Plans To Unblind Hero And Ole Data To Inform Path Forward Following FDA Clinical Hold
Aardvark Therapeutics Q1 net loss widens
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Aardvark pauses two obesity drug trials as it reviews side effects
Brief: Aardvark Therapeutics Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Business Updates
Aardvark Therapeutics reports lower-than-expected 2025 net loss
Street View: Aardvark slides after pausing late-stage trial; multiple analysts cut PT
U.S. RESEARCH ROUNDUP- Aardvark Therapeutics, Chevron, Crowdstrike
Aardvark Therapeutics falls after pausing late-stage rare disease trial
NASDAQ RESUMED AT 04:41 PM
Brief: Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome